Loading
NASDAQHealthcareBiotechnology
Latest quote
$2.71
−$0.01 · -0.37%
Sana Biotechnology, Inc. is a biotechnology firm focused on creating treatments using engineered cells. The company develops advanced ex vivo and in vivo cell engineering platforms to address a range of conditions with significant unmet medical needs, including various cancers, diabetes, central nervous system disorders, cardiovascular diseases, and genetic illnesses. Its portfolio of drug candidates includes SG295 and SG242, which are designed to target CD19+ cancer cells involved in non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia. For multiple myeloma, Sana is progressing SG221, SG239, and SC255. Other pipeline assets include SG328 for ornithine transcarbamylase deficiency, and SG418 for sickle cell disease and beta-thalassemia. Additionally, the company is advancing SC291, a CD19 allogeneic T cell therapy, SC451 for type I diabetes mellitus, and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Founded in 2018 as FD Therapeutics, Inc., the company adopted its current name, Sana Biotechnology, Inc., in September 2018 and is based in Seattle, Washington.
Regular session
$2.71
−$0.01 · -0.37%
Regular session · ET · Market data may be delayed.
Sana Biotechnology, Inc. is a biotechnology firm focused on creating treatments using engineered cells. The company develops advanced ex vivo and in vivo cell engineering platforms to address a range of conditions with significant unmet medical needs, including various cancers, diabetes, central nervous system disorders, cardiovascular diseases, and genetic illnesses. Its portfolio of drug candidates includes SG295 and SG242, which are designed to target CD19+ cancer cells involved in non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia. For multiple myeloma, Sana is progressing SG221, SG239, and SC255. Other pipeline assets include SG328 for ornithine transcarbamylase deficiency, and SG418 for sickle cell disease and beta-thalassemia. Additionally, the company is advancing SC291, a CD19 allogeneic T cell therapy, SC451 for type I diabetes mellitus, and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Founded in 2018 as FD Therapeutics, Inc., the company adopted its current name, Sana Biotechnology, Inc., in September 2018 and is based in Seattle, Washington.
Day range
Current $2.71
52-week range
Current $2.71
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
27
Expensive
Sentiment
54
Mixed
Risk
71
High Risk
Momentum
51
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Sana Biotechnology, Inc. is a biotechnology firm focused on creating treatments using engineered cells. The company develops advanced ex vivo and in vivo cell engineering platforms to address a range of conditions with significant unmet medical needs, including various cancers, diabetes, central nervous system disorders, cardiovascular diseases, and genetic illnesses. Its portfolio of drug candidates includes SG295 and SG242, which are designed to target CD19+ cancer cells involved in non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia. For multiple myeloma, Sana is progressing SG221, SG239, and SC255. Other pipeline assets include SG328 for ornithine transcarbamylase deficiency, and SG418 for sickle cell disease and beta-thalassemia. Additionally, the company is advancing SC291, a CD19 allogeneic T cell therapy, SC451 for type I diabetes mellitus, and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Founded in 2018 as FD Therapeutics, Inc., the company adopted its current name, Sana Biotechnology, Inc., in September 2018 and is based in Seattle, Washington.
Day range
Current $2.71
52-week range
Current $2.71
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 12.75M USD | — | — | — | — |
| Gross profit | −12.75M USD | — | — | — | — |
| Research and development | 131.98M USD | 208.68M USD | 219.84M USD | 201M USD | 306.5M USD |
| Selling, general, and administrative | 44.3M USD | 64.04M USD | 73.3M USD | 71.56M USD | 50.41M USD |
| Operating expenses | 178.21M USD | 272.72M USD | 293.14M USD | 272.56M USD | 356.91M USD |
| Interest income | 3.85M USD | 10.47M USD | 9.94M USD | 3.76M USD | 676K USD |
| Depreciation and amortization | 12.75M USD | 15.5M USD | 24.56M USD | 15.63M USD | 11.07M USD |
| Operating income | −190.96M USD | −272.72M USD | −293.14M USD | −272.56M USD | −356.91M USD |
| Net income | −244.17M USD | −266.76M USD | −283.26M USD | −269.48M USD | −355.93M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$7.00
158.30% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI24.19M0.00%2.3T USD0.03%$379.52-0.40%
State Street SPDR S&P Biotech ETFXBI15.73M0.15%10.08B USD0.35%$147.01-2.14%
iShares Russell 2000 ETFIWM12.34M0.02%78.56B USD0.19%$274.8-1.04%
Vanguard Extended Market ETFVXF7.61M0.01%95.4B USD0.05%$231.42-0.89%
iShares Russell 2000 Growth ETFIWO4.39M0.03%14.25B USD0.24%$350.63-1.34%
Vanguard Russell 2000 ETFVTWO4.08M0.02%18B USD0.06%$110.99-1.09%
iShares Biotechnology ETFIBB3.79M0.04%10.4B USD0.44%$197.82-2.71%
Schwab U.S. Small-Cap ETFSCHA2.71M0.01%21.7B USD0.03%$32.305-0.94%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
